Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
Charles Frost,Jessie Wang,Sunil Nepal,Alan Schuster,Yu Chen Barrett,Rogelio Mosqueda-Garcia,Richard A. Reeves,Frank LaCreta +7 more
TLDR
To evaluate apixaban single dose safety, tolerability, pharmacokinetics and pharmacodynamics and assess the effect of food on Apixaban pharmacokinetically, a large number of animals were tested.Abstract:
Aims
To evaluate apixaban single dose safety, tolerability, pharmacokinetics and pharmacodynamics and assess the effect of food on apixaban pharmacokinetics.read more
Citations
More filters
Journal ArticleDOI
Old and new oral anticoagulants: Food, herbal medicines and drug interactions
Alessandro Di Minno,Beatrice Frigerio,Gaia Spadarella,Alessio Ravani,Daniela Sansaro,Mauro Amato,Joseph P Kitzmiller,Mauro Pepi,Elena Tremoli,Damiano Baldassarre +9 more
TL;DR: A critical review of VKAs and DOACs with focus on their potential for interactions with drugs, foods, herbs and over-the-counter medications is presented.
Journal ArticleDOI
Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban
Inna Y. Gong,Richard B. Kim +1 more
TL;DR: By better understanding the effect of clinical variables such as age, renal function, dosing interval, and drug metabolism, the authors might be able to better predict the risk for sub- and supratherapeutic anticoagulation response and individualize OAC selection and dosing.
Journal ArticleDOI
Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies
TL;DR: Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies are defined and the managed strategies are outlined.
Journal ArticleDOI
Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human Blood
Gines Escolar,Victor Fernandez-Gallego,Eduardo Arellano-Rodrigo,Jaume Roquer,Joan Carles Reverter,Victoria Veronica Sanz,Patricia Molina,Irene Lopez-Vilchez,Maribel Diaz-Ricart,Ana M. Galan +9 more
TL;DR: The results indicate that rFVIIa, PCCs and aPCCs have the potential to restore platelet and fibrin components of the hemostasis previously altered by apixaban.
Journal ArticleDOI
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
TL;DR: The pharmacokinetic, pharmacodynamic, biopharmaceutical, and drug–drug interaction profiles of apixaban are provided, and the population-pharmacokinetic analyses of Apixaban in both healthy subjects and in the target patient populations are discussed.
References
More filters
Journal ArticleDOI
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger,John H. Alexander,Renato D. Lopes,Elaine M. Hylek,Michael G. Hanna,Hussein R. Al-Khalidi,Jack Ansell,Dan Atar,Alvaro Avezum,M. Cecilia Bahit,Rafael Diaz,J. Donald Easton,Justin A. Ezekowitz,Greg C. Flaker,David A. Garcia,Margarida Geraldes,Bernard J. Gersh,Sergey P. Golitsyn,Shinya Goto,Antonio G. Hermosillo,Stefan H. Hohnloser,John D. Horowitz,Puneet Mohan,Petr Jansky,Basil S. Lewis,Jose Lopez-Sendon,Prem Pais,Alexander Parkhomenko,Jun Zhu,Lars Wallentin +29 more
TL;DR: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.
Journal ArticleDOI
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly,John W. Eikelboom,Campbell D. Joyner,Hans-Christoph Diener,Robert G. Hart,Sergey P. Golitsyn,Greg C. Flaker,Alvaro Avezum,Stefan H. Hohnloser,Rafael Diaz,Mario Talajic,Jun Zhu,Prem Pais,Andrzej Budaj,Alexander Parkhomenko,Petr Jansky,Patrick J. Commerford,Ru San Tan,Kui-Hian Sim,Basil S. Lewis,Walter Van Mieghem,Jae Hyung Kim,Fernando Lanas-Zanetti,Antonio Gonzalez-Hermosillo,Antonio L. Dans,Muhammad Munawar,John H. Lawrence,Gayle Lewis,Rizwan Afzal,Salim Yusuf +29 more
TL;DR: In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing therisk of major bleeding or intracranial hemorrhage.
Journal ArticleDOI
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
TL;DR: Guyatt et al. as mentioned in this paper presented the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) and provided specific management recommendations for the first 1 or 2 days for most individuals.
Journal ArticleDOI
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
TL;DR: Apixaban 2.5 mg twice daily, starting on the morning after total knee replacement, offers a convenient and more effective orally administered alternative to 40 mg per day enoxaparin, without increased bleeding.
Journal ArticleDOI
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
Michael R. Lassen,Alexander Gallus,Gary E. Raskob,Graham F. Pineo,Dalei Chen,Luz Margarita Ramirez +5 more
TL;DR: Among patients undergoing hip replacement, thromboprophylaxis with apixaban, as compared with enoxaparin, was associated with lower rates of venous thromboembolism, without increased bleeding.
Related Papers (5)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger,John H. Alexander,Renato D. Lopes,Elaine M. Hylek,Michael G. Hanna,Hussein R. Al-Khalidi,Jack Ansell,Dan Atar,Alvaro Avezum,M. Cecilia Bahit,Rafael Diaz,J. Donald Easton,Justin A. Ezekowitz,Greg C. Flaker,David A. Garcia,Margarida Geraldes,Bernard J. Gersh,Sergey P. Golitsyn,Shinya Goto,Antonio G. Hermosillo,Stefan H. Hohnloser,John D. Horowitz,Puneet Mohan,Petr Jansky,Basil S. Lewis,Jose Lopez-Sendon,Prem Pais,Alexander Parkhomenko,Jun Zhu,Lars Wallentin +29 more
Dabigatran versus warfarin in patients with atrial fibrillation
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly,John W. Eikelboom,Campbell D. Joyner,Hans-Christoph Diener,Robert G. Hart,Sergey P. Golitsyn,Greg C. Flaker,Alvaro Avezum,Stefan H. Hohnloser,Rafael Diaz,Mario Talajic,Jun Zhu,Prem Pais,Andrzej Budaj,Alexander Parkhomenko,Petr Jansky,Patrick J. Commerford,Ru San Tan,Kui-Hian Sim,Basil S. Lewis,Walter Van Mieghem,Jae Hyung Kim,Fernando Lanas-Zanetti,Antonio Gonzalez-Hermosillo,Antonio L. Dans,Muhammad Munawar,John H. Lawrence,Gayle Lewis,Rizwan Afzal,Salim Yusuf +29 more